These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 18403900

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs.
    Satoh K, Ichihara K.
    J Cardiovasc Pharmacol; 2000 Feb; 35(2):256-62. PubMed ID: 10672858
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
    Bulhak A, Roy J, Hedin U, Sjöquist PO, Pernow J.
    Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of medium pH on the cytotoxicity of hydrophilic statins.
    Kobayashi M, Kagawa T, Takano R, Itagaki S, Hirano T, Iseki K.
    J Pharm Pharm Sci; 2007 Jun; 10(3):332-9. PubMed ID: 17727796
    [Abstract] [Full Text] [Related]

  • 7. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs.
    Ichihara K, Satoh K, Abiko Y.
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):852-6. PubMed ID: 7509904
    [Abstract] [Full Text] [Related]

  • 8. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
    Kilic U, Bassetti CL, Kilic E, Xing H, Wang Z, Hermann DM.
    Neuroscience; 2005 Dec; 134(3):901-6. PubMed ID: 16009498
    [Abstract] [Full Text] [Related]

  • 9. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats.
    Ikeda Y, Young LH, Lefer AM.
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):649-56. PubMed ID: 12658068
    [Abstract] [Full Text] [Related]

  • 10. [Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
    Ichihara K, Satoh K, Yamamoto A, Hoshi K.
    Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():142P-149P. PubMed ID: 10629871
    [Abstract] [Full Text] [Related]

  • 11. Rosuvastatin: characterization of induced myopathy in the rat.
    Westwood FR, Scott RC, Marsden AM, Bigley A, Randall K.
    Toxicol Pathol; 2008 Feb; 36(2):345-52. PubMed ID: 18362199
    [Abstract] [Full Text] [Related]

  • 12. Genotoxicity evaluation of HMG CoA reductase inhibitor rosuvastatin.
    Berber AA, Celik M, Aksoy H.
    Drug Chem Toxicol; 2014 Jul; 37(3):316-21. PubMed ID: 24245812
    [Abstract] [Full Text] [Related]

  • 13. Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study.
    Liuni A, Luca MC, Gori T, Parker JD.
    Am J Physiol Heart Circ Physiol; 2012 Jan 01; 302(1):H153-8. PubMed ID: 22003053
    [Abstract] [Full Text] [Related]

  • 14. Role of multi-drug resistance-associated protein-1 transporter in statin-induced myopathy.
    Dorajoo Rs, Pereira BP, Yu Z, Gopalakrishnakone P, Leong CC, Wee A, Lee E.
    Life Sci; 2008 Apr 09; 82(15-16):823-30. PubMed ID: 18509883
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats.
    Ansari JA, Bhandari U, Haque SE, Pillai KK.
    Toxicol Mech Methods; 2012 Jan 09; 22(1):67-73. PubMed ID: 21859367
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
    McKenney JM.
    Am J Health Syst Pharm; 2005 May 15; 62(10):1033-47. PubMed ID: 15901588
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M.
    Am J Cardiol; 2001 Mar 08; 87(5A):28B-32B. PubMed ID: 11256847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.